9/13/2021 7:48:15 AM
ATyr Pharma Announces Phase 1b/2a Trial Of ATYR1923 Meets Primary Endpoint
12/21/2020 7:19:17 AM
ATyr Pharma Completes Enrollment In Phase 1b/2a Clinical Trial Of ATYR1923 In Pulmonary Sarcoidosis; Sees Data In Q3
9/14/2020 8:20:25 AM
ATyr Plans Sale Of Up To $20 Mln Of Common Stock To Aspire Capital Fund, LLC
8/11/2020 7:19:22 AM
ATyr Pharma Partner Kyorin Proceeds To Phase 1 Trial Of ATYR1923 In Japan
6/15/2020 7:15:46 AM
ATyr Pharma Doses First Patient In Phase 2 Study Evaluating ATYR1923, In COVID-19 Patients
4/21/2020 8:39:44 AM
ATyr: FDA Accepts IND Application On ATYR1923 In Phase 2 Study For COVID-19
3/17/2020 8:42:23 AM
ATyr Pharma Appoints Arthur Mercurio As A Scientific Advisor
2/6/2020 9:08:27 AM
ATyr Pharma Reports Pricing Of $18 Mln Public Offering
1/6/2020 8:23:53 AM
ATyr Pharma Enters Collaboration And License Agreement With Kyorin